Kindred Bio (KIN) Announces Appointment Of Jennifer Elliott As Vice President Of Legal Affairs And Intellectual Property

SAN FRANCISCO, May 28, 2015 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN) today announced the appointment of Jennifer Elliott as Vice President of Legal Affairs and Intellectual Property.

Dr. Elliott joins KindredBio from Genentech, where she most recently served as Associate General Counsel and Director of Patent Law. She had increasing levels of responsibility in her nearly 10 year tenure with Genentech, and most recently oversaw Genentech's oncology intellectual property group. She has had an extensive intellectual property practice throughout her career, with a particular focus on biologics and antibodies. Prior to her role her at Genentech, Dr. Elliott was an Associate at Finnegan, Henderson, Farabow, Garrett and Dunner, LLP and a Technical Expert at Lahive & Cockfield LLP. She holds a Ph.D. in Microbiology and Molecular Genetics from Harvard University and a J.D. from Stanford Law School.

Richard Chin, Chief Executive Officer of KindredBio, stated, "We are extremely pleased to welcome Jennifer onto KindredBio's team as we build one of the world's leading portfolios of veterinary intellectual property."

About Kindred Biosciences

Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.


Denise Bevers
[email protected]
(650) 701-7904


Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.